Literature DB >> 30158063

Treatment efficacy between total thyroidectomy and lobectomy for patients with papillary thyroid microcarcinoma: A systemic review and meta-analysis.

Wuping Zheng1, Jingtai Li1, Pengfei Lv1, Zhilin Chen1, Pingming Fan2.   

Abstract

INTRODUCTION: This systemic review and meta-analysis was to determine whether the recurrence and mortality rates in papillary thyroid microcarcinoma (PTMC) patients were lower when treated with total thyroidectomy (TT) compared to thyroid lobectomy (TL).
METHODS: Using PubMed, Cochrane library and EMBASE databases, we conducted a meta-analysis to assess the clinical outcomes in patients with PTMC based on surgical mode. The relative risk (RR) and 95% confidence interval (CI) were calculated for this meta-analysis.
RESULTS: A total of 11 cohort studies that comprised of 13,801 patients met the inclusion criteria for this systematic review and meta-analysis. Overall, low recurrence rates were observed in the TT group compared to the TL group (RR = 0.57, 95% CI = 0.35 to 0.94, Pheterogeneity = 0.002, I2 = 65.2%), however, no significant differences were observed between the two surgical methods for mortality rates (RR = 0.84, 95% CI = 0.27 to 2.54, Pheterogeneity = 0.023, I2 = 68.5%). For subgroup analysis based on country and sample size, no significant differences were observed between the two groups for recurrence rates.
CONCLUSION: Our meta-analysis indicates that patients who underwent thyroid lobectomy had an increased risk of recurrence but not mortality compared to patients who had total thyroidectomy for papillary thyroid microcarcinoma.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Lobectomy; Meta-analysis; Papillary thyroid microcarcinoma; Systematic review; Total thyroidectomy

Mesh:

Year:  2018        PMID: 30158063     DOI: 10.1016/j.ejso.2018.08.004

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Recurrence-free survival after total thyroidectomy and lobectomy in patients with papillary thyroid microcarcinoma.

Authors:  M van Gerwen; M Alsen; E Lee; C Sinclair; E Genden; E Taioli
Journal:  J Endocrinol Invest       Date:  2020-07-10       Impact factor: 4.256

2.  Complication Rates of Total Thyroidectomy vs Hemithyroidectomy for Treatment of Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.

Authors:  Vivian Hsiao; Tyler J Light; Abdullah A Adil; Michael Tao; Alexander S Chiu; Mary Hitchcock; Natalia Arroyo; Sara Fernandes-Taylor; David O Francis
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-06-01       Impact factor: 8.961

3.  Impact of prophylactic unilateral central neck dissection needed for patients with papillary thyroid microcarcinoma.

Authors:  Young Jae Ryu; Jung Han Yoon
Journal:  Gland Surg       Date:  2020-04

4.  Characteristics and Management of Papillary Thyroid Microcarcinoma in the United Arab Emirates: Experience from a Large Tertiary Hospital.

Authors:  Azhar A Malik; Faisal Aziz; Salem A Beshyah; Khaled M Aldahmani
Journal:  Saudi J Med Med Sci       Date:  2022-01-17

5.  Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.

Authors:  Wasit Kanokwongnuwat; Noppadol Larbcharoensub; Chutintorn Sriphrapradang; Chaiyawat Suppasilp; Kanungnij Thamnirat; Chaninart Sakulpisuti; Arpakorn Kositwattanarerk; Chirawat Utamakul; Chanika Sritara; Wichana Chamroonrat
Journal:  Endocrine       Date:  2022-04-27       Impact factor: 3.925

6.  Total thyroidectomy versus lobectomy for papillary thyroid cancer: A systematic review and meta-analysis.

Authors:  Chi Zhang; Yanshuang Li; Jiyu Li; Xiao Chen
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

7.  Extent of Surgery and the Prognosis of Unilateral Papillary Thyroid Microcarcinoma.

Authors:  Hengqiang Zhao; Le Cui
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.